The phase III KEYNOTE-859 trial has shown that the addition of first-line pembrolizumab to chemotherapy was associated with a statistically significant improvement in overall survival in patients with HER2-negative advanced gastric/gastroesophageal junction adenocarcinoma.
#gastriccancer, #pembrolizumab, #keynote859
Treatment with platinum-based chemotherapy prior to chemoradiation improved PFS and OS compared with chemoradiation alone in patients with locally advanced cervical cancer. @ucl@myesmo#ESMO23#gyncsm https://t.co/Beeq1W4lRR
Increased incidence in radiation ☢️ necrosis when delivered 7 days before to 21 days after ADC.
Symptomatic Necrosis With ADCs and Concurrent Stereotactic Radiotherapy for Brain Metastases | Targeted and Immune Cancer Therapy | JAMA Oncology
#bcsm https://t.co/x6G8volGcs
The EMA’s CHMP has recommended the approval of brentuximab vedotin in combination with doxorubicin, vinblastine, and dacarbazine in adult patients with previously untreated, CD30-positive, stage III Hodgkin lymphoma. @EMA_News#lymsm#oncology https://t.co/vXE4xwhGCd